CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Protara Therapeutics, Inc. - TARA CFD

2.31
0.86%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026262 %
Charges from full value of position ($-4.99)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00404 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00404%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.33
Open 2.35
1-Year Change -5.62%
Day's Range 2.22 - 2.45
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 12, 2024 2.31 -0.04 -1.70% 2.35 2.46 2.19
Jul 11, 2024 2.33 -0.05 -2.10% 2.38 2.44 2.22
Jul 10, 2024 2.27 0.15 7.08% 2.12 2.30 2.08
Jul 9, 2024 2.11 0.06 2.93% 2.05 2.23 2.01
Jul 8, 2024 2.05 -0.01 -0.49% 2.06 2.12 2.04
Jul 5, 2024 2.05 -0.01 -0.49% 2.06 2.06 1.93
Jul 3, 2024 2.08 0.07 3.48% 2.01 2.08 1.95
Jul 2, 2024 2.01 -0.02 -0.99% 2.03 2.05 1.96
Jul 1, 2024 2.07 -0.08 -3.72% 2.15 2.15 1.99
Jun 28, 2024 2.03 -0.17 -7.73% 2.20 2.21 1.99
Jun 27, 2024 2.13 0.24 12.70% 1.89 2.28 1.89
Jun 26, 2024 1.93 -0.10 -4.93% 2.03 2.03 1.84
Jun 25, 2024 2.06 -0.18 -8.04% 2.24 2.29 2.04
Jun 24, 2024 2.21 0.02 0.91% 2.19 2.27 2.18
Jun 21, 2024 2.25 -0.18 -7.41% 2.43 2.47 2.23
Jun 20, 2024 2.39 0.15 6.70% 2.24 2.51 2.20
Jun 18, 2024 2.32 -0.16 -6.45% 2.48 2.52 2.32
Jun 17, 2024 2.46 -0.05 -1.99% 2.51 2.54 2.35
Jun 14, 2024 2.53 -0.02 -0.78% 2.55 2.58 2.48
Jun 13, 2024 2.58 -0.06 -2.27% 2.64 2.64 2.53

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Protara Therapeutics, Inc. Company profile

About Protara Therapeutics Inc

Protara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying therapies for the treatment of cancer and rare diseases. The Company's pipeline includes TARA-002, IV Choline Chloride and Vonapanitase. The Company's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is intravenous (IV) substrate replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD). Vonapanitase is a recombinant human elastase that are developing for the improvement of vascular access outcomes in patients with chronic kidney disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Protara Therapeutics Inc revenues was not reported. Net loss increased 39% to $47.3M. Higher net loss reflects Research and development - other increase of 75% to $19.7M (expense), General and administrative - other increase of 30% to $17.4M (expense), Stock-based Compensation in Research and increase of 90% to $1.4M (expense).

Industry: Bio Therapeutic Drugs

345 Park Avenue South
3rd Floor
NEW YORK
NEW YORK 10010
US

People also watch

XRP/USD

0.54 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,342.46 Price
+4.300% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,410.66 Price
-0.040% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.60

US100

20,403.20 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading